LAYOFFS...

Quote


Derm has an couple things going for it.
1. Outstanding pipeline for sure. Great results w abro vs dupixent as comparator in severe AD. Alopecia and vitaligo drugs in phase 2/3. Some other compounds as well in phase 1.
2. Eucrisa performing as expected. New indication for 3-24 months (where the AD is diagnosed).
3. Division is set up a one rep per Territory.

Could collapse some territories for sure. Especially in areas where we can now see after 3 years if it’s not profitable.
 
anonymous said:
Derm has an couple things going for it.
1. Outstanding pipeline for sure. Great results w abro vs dupixent as comparator in severe AD. Alopecia and vitaligo drugs in phase 2/3. Some other compounds as well in phase 1.
2. Eucrisa performing as expected. New indication for 3-24 months (where the AD is diagnosed).
3. Division is set up a one rep per Territory.

Could collapse some territories for sure. Especially in areas where we can now see after 3 years if it’s not profitable.
Click to expand...
Hugh really! 360 reps to sell 100mil yr cream and new indications will drive little sales while Alpecia has just a few thousand patients
 
anonymous said:
If there is a reorg, it will be industry-wide. You can’t run or hide.
Click to expand...

I hope our colleagues realize this. Too many mouth off about how invaluable we are, blah blah blah. Come October, we shall see....
 
anonymous said:
The Derm division is a joke.
Click to expand...
Yes its a joke to sell a cream in a 10sec stand off sample drop like PC/IM & get paid like a specialty rep. Most simple product Pfizer makes and a grade school kid can sell.

Its a toss up which division is over weighted w reps. DERMS 350 or Xeljanz 267....
Both only need 40-50% of that number so both likely will be gutted in the Fall/Winter layoffs.
(Dont reply about a Alpecia drug that only few hundred pts have or the Jak1 2x a day that will compete w gold standard 1x month shot- soon to be once every 3 month shot.... its a joke. Also JAK 1 is showing severe SE to the clean safety of Gold Standard...)

Both divisions need 50-60% cuts but crazy marketing never sales VP is all about share of voice & wouldnt doubt if he wants to Triple both divisions knowing his brillance
 
anonymous said:
I hope our colleagues realize this. Too many mouth off about how invaluable we are, blah blah blah. Come October, we shall see....
Click to expand...
Those collegues are Young, clueless , with zero business IQ. This virtual format shows how invaluable a rep is LOL. Many can be replaced w vitural rep in a cubic at HQ.
 
anonymous said:
Those collegues are Young, clueless , with zero business IQ. This virtual format shows how invaluable a rep is LOL. Many can be replaced w vitural rep in a cubic at HQ.
Click to expand...

is that right? please tell me how many VCCs you have done since we have been out of the field. my guess is zero, or perhaps one which was not compliant. amirite?
 
There are not 350 reps in derm. Off by about 120. And it’s not a 10 sec stand up. The landscape is not that simple. Have to keep it mind competing w generic environment. Also dealing with non compliant patients by nature of disease. This is a long game... eczema doesn’t go away. They aren’t coming in if they think they have a flare. They have let it go until they are making and appointment and paying a copay to be seen. By this time it’s bad. Not to mention getting the Rx. The specialty pharmacy environment is a whole other conversation not to mention the hurdles of Medicaid and the managed Medicaids that none of the offices even know what is required for each plan. Then throw in the managed Medicaid plans actually counter detailing the HCPs on not using Eucrisa.
Coming from PC side, was an easier sell back then.
 
anonymous said:
There are not 350 reps in derm. Off by about 120. And it’s not a 10 sec stand up. The landscape is not that simple. Have to keep it mind competing w generic environment. Also dealing with non compliant patients by nature of disease. This is a long game... eczema doesn’t go away. They aren’t coming in if they think they have a flare. They have let it go until they are making and appointment and paying a copay to be seen. By this time it’s bad. Not to mention getting the Rx. The specialty pharmacy environment is a whole other conversation not to mention the hurdles of Medicaid and the managed Medicaids that none of the offices even know what is required for each plan. Then throw in the managed Medicaid plans actually counter detailing the HCPs on not using Eucrisa.
Coming from PC side, was an easier sell back then.
Click to expand...
Nice try to justify your PC level job selling the most simplistic drug in the company.
Derm makes 100mil which is a joke in the 4th year. Pfe normally sells off or selves any product that doesn't generate min 500million a yr.
Derm is a joke & wast of money while being the lowest ROI in the history of Pfizer per headcount and for a $9Billion drug purchase.

Derm is 1st division to be rightfully axed !
Vaccine and Xeljanz next two.
 
anonymous said:
Nice try to justify your PC level job selling the most simplistic drug in the company.
Derm makes 100mil which is a joke in the 4th year. Pfe normally sells off or selves any product that doesn't generate min 500million a yr.
Derm is a joke & wast of money while being the lowest ROI in the history of Pfizer per headcount and for a $9Billion drug purchase.

Derm is 1st division to be rightfully axed !
Vaccine and Xeljanz next two.
Click to expand...
Derm is absolutely not a speciality position, regardless of the job description. It is no more sophisticated than an OTC division.
The challenges listed in a previous post are humorous- all products have challenges- most are much more difficult than being counter detailed. Are you kidding me?

It is disgusting that division has bled money for so long. The pipeline has very limited potential.
 
NEWS FLASH..... Vaccines isn't going anywhere... we have a billion plus product and another one coming soon..... headcount is less than 300+- vacancies... and if Cdif is approved we will have 10 more years at least.... not to mention a covid 19 candidate.....
 
anonymous said:
NEWS FLASH..... Vaccines isn't going anywhere... we have a billion plus product and another one coming soon..... headcount is less than 300+- vacancies... and if Cdif is approved we will have 10 more years at least.... not to mention a covid 19 candidate.....
Click to expand...

plus with a competitor coming soon they need us more than ever
 
I think you guys in vaccines have a job for a long time. Thought about jumping but I heard it was same stupid PFE bots in Management ireach and freq and I got that already. Heard PC managers have screwed division up with yes people from PC who dont know any different...No bump in pay either... Is Vaccines a speciality position? Why not?
 
anonymous said:
Derm is absolutely not a speciality position, regardless of the job description. It is no more sophisticated than an OTC division.
The challenges listed in a previous post are humorous- all products have challenges- most are much more difficult than being counter detailed. Are you kidding me?

It is disgusting that division has bled money for so long. The pipeline has very limited potential.
Click to expand...
20 years ago, PFE stood for 4 things:
Men
Military
Money
Mormon
 
I find it amusing how different divisions are justifying their worth in the company. Given the new environment that will evolve I believe most divisions will be at risk for cuts. Oncology may be left alone.
Finally, calling on derms is probably the easiest specialist to call on. So to say their job is so challenging I find humorous. I do realize their struggle lies within managed markets
 


Write your reply...
Top Bottom
Back
Quote